Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
McArthur, Grant A, Prof, Chapman, Paul B, Prof, Robert, Caroline, MD, Larkin, James, MD, Haanen, John B, MD, Dummer, Reinhard, Prof, Ribas, Antoni, Prof, Hogg, David, Prof, Hamid, Omid, MD, Ascierto, Paolo A, MD, Garbe, Claus, Prof, Testori, Alessandro, MD, Maio, Michele, MD, Lorigan, Paul, MD, Lebbé, Celeste, Prof, Jouary, Thomas, MD, Schadendorf, Dirk, Prof, O'Day, Stephen J, MD, Kirkwood, John M., Prof, Eggermont, Alexander M, Prof, Dréno, Brigitte, Prof, Sosman, Jeffrey A, Prof, Flaherty, Keith T, MD, Yin, Ming, PhD, Caro, Ivor, MD, Cheng, Suzanne, PhD, Trunzer, Kerstin, PhD, Hauschild, Axel, Prof
Published in The lancet oncology (01.03.2014)
Published in The lancet oncology (01.03.2014)
Get full text
Journal Article